Switching appropriate patients with type 2 diabetes to alogliptin from existing DPP-4 inhibitors: experience and outcomes from three Clinical Commissioning Groups and Local Health Boards

Final version - Takeda supplement

Information for healthcare professionals only.

Content for healthcare professionals

Access to this content is restricted to UK-based doctors, nurses, and pharmacists

If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one. 

Return to homepage